Skip to content
Screener

Innoviva, Inc. INVA External Services — Research And Development Expense

Similar metrics at other companies

Beam Therapeutics logo
BEAMExternal Research And Development Expenses — Research And Development Expense
$30.08M-12.6%
Rapport Therapeutics, Inc. logo
RAPPRAP219Program External Expenses — Research And Development Expense
$34.09M+252%
Disc Medicine logo
IRONInternal Research And Development — Research And Development Expense
$11.31M+67.6%
Solid Biosciences Inc. logo
SLDBInternal Research And Development Expense — Research And Development Expense
$9.06M+33.9%
Rapport Therapeutics, Inc. logo
RAPPPreclinical Programs External Expenses — Research And Development Expense
$4.87M+3.1%
Solid Biosciences Inc. logo
SLDBExternal General And Administrative Expense — Research And Development Expense
$4.87M-3.2%

Other financials

Income statement

See full
Revenue$119.6M+19.3%
Gross profit$90.6M+9.0%
Operating income$50.9M+4.3%
Net income-$83.4M-231%
EPS (diluted)-$1.14-248%

Balance sheet

See full
Cash & equivalents$570.4M+43.5%
Total debt$269.7M-40.2%
Total equity$1.2B
Total assets$1.7B+27.7%

Cash flow

See full
Operating cash flow$52.0M+17.9%
CapEx$429.0K
Free cash flow$51.5M+16.9%

Valuation

See full
Market cap$1.53B+33.1%
Enterprise value$1.22B+2.1%
P/E4.3×-25.4×
P/S3.5×+0.4×

Profitability

See full
Gross margin72.2%-10.9pp
Operating margin36.9%-10.7pp
Net margin81.2%+70.8pp
FCF margin43.1%-11.1pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio16×+13.4×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:26 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335235
(In thousands)Three months ended June 30, 2026Three months ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Amortization of acquired intangible assets6,6266,54713,18013,022
Selling and marketing10,3358,14719,83716,218
General and administrative24,23618,26547,17237,685
Research and development - External services and expenses2,4636,7825,0699,833
Research and development - Internal expenses2,7271,2015,3622,546
Changes in fair values of equity method investments, net131,834(13,082)(25,816)467
Changes in fair values of equity and long-term investments, net29,153(11,280)(4,422)54,019
Interest and dividend income(7,599)(4,925)(18,586)(9,463)

Item 1. Financial Statements

FAQ

What is Innoviva, Inc.'s external services — research and development expense?
Innoviva, Inc. (INVA) reported external services — research and development expense of $2.46M in Q2 2026.
How has Innoviva, Inc.'s external services — research and development expense changed year-over-year?
Innoviva, Inc.'s external services — research and development expense decreased by 63.7% year-over-year, from $6.78M to $2.46M.
What is the long-term trend for Innoviva, Inc.'s external services — research and development expense?
Over 3 years (2022 to 2025), Innoviva, Inc.'s external services — research and development expense has grown at a -14.0% compound annual growth rate (CAGR), from $24.67M to $15.71M.
What does external services — research and development expense mean?
This metric represents the total costs incurred by the External Services segment for research and development activities, including clinical trials, product development, and scientific innovation efforts. It reflects the company's investment in advancing its healthcare asset pipeline and maintaining the competitive viability of its specialized service offerings. Monitoring this expense helps investors assess the segment's commitment to long-term growth and its capacity to innovate within the critical care and infectious disease markets.

Ask your AI about Innoviva, Inc.'s external services — research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude